ArticleToxicology reports2025
Feasibility assessment of a pharmaco-kinetic behavior based yield model of salivary cotinine among tobacco users.
Article in Toxicology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Losartan in the Era of Emerging Contaminants: A Multi-Criteria Approach for Efficient and Sustainable Remediation.Molecules (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Methods: A secondary analysis was conducted using puff topography and salivary cotinine biomarker data from a prior two arm, two period cross-over study conducted in the natural environment over 17 days which enrolled 55 Juul electronic cigarette users. The study expands upon a previously validated behavior-based yield (BBY) which quantified aerosol emissions from a Juul ecig as a function of user behavior. A Pharmacokinetic Behavior-Based Yield (PkBBY) model is introduced which models the uptake of nicotine into the body and its subsequent metabolic decay into cotinine. A subset of the available participant data was used to train the PkBBY model and identify three parameters: a gain reflecting the conversion of nicotine into salivary cotinine concentration, and the half-lives of nicotine and salivary cotinine in the body. A separate subset of the available data was used for assessing performance of the PkBBY model against salivary cotinine biomarkers of exposure. Results: Model training demonstrated the PkBBY model was able to predict the bedtime salivary cotinine of participants within + /- 220 ng/mL 95 % confidence interval on the regression, based on their observed puff topography. The training algorithm estimated the conversion from nicotine ingested into the concentration of salivary cotinine as 28.8 [(ng/mL cotinine)/(mg nicotine ingested)], and the half-lives of nicotine and cotinine to be 4.4 and 49 [hours], respectively. The one-to-one intraclass correlation coefficient of the model applied to the assessment data set was 0.6, indicating moderate agreement between the predictions and the observed biomarkers, Limitations of the model associated with the data available for secondary analysis are discussed. Conclusions: The PkBBY model was internally validated and shows promise as a tool for establishing a causal relationship between puffing behavior and an established biomarker of nicotine exposure. Further work is needed to develop personalized PkBBY model parameters to account for variations in participant metabolism factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.